AR035345A1 - Compuestos derivados de pirazol, composicion farmaceutica, compuestos intermediarios - Google Patents

Compuestos derivados de pirazol, composicion farmaceutica, compuestos intermediarios

Info

Publication number
AR035345A1
AR035345A1 ARP010104115A ARP010104115A AR035345A1 AR 035345 A1 AR035345 A1 AR 035345A1 AR P010104115 A ARP010104115 A AR P010104115A AR P010104115 A ARP010104115 A AR P010104115A AR 035345 A1 AR035345 A1 AR 035345A1
Authority
AR
Argentina
Prior art keywords
straight
members
branched chain
independently selected
nr7r8
Prior art date
Application number
ARP010104115A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR035345A1 publication Critical patent/AR035345A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de la fórmula (1) donde R1 es un alquilo C1-8 de cadena lineal o ramificada, un alquenilo C2-8 de cadena lineal o ramificada, un alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo (3-8 miembros), bicicloalquilo C5-11, bicicloalquenilo C7-11, o heterobicicloalquilo (5-11 miembros); y donde R1 está opcionalmente sustituido con 1 a 6 sustituyentes R5 independientemente seleccionados de F, Cl, Br, I, nitro, ciano, -CF3, -NR7R8, -NR7C(=O)R8, -NR7C(=O)OR8, -NR7C(=O)NR8R9, -NR7S(=O)2R8, -NR7S(=O)2NR8R9, -OR7, OC(=O)R7, -OC(=O)OR7, -C(=O)OR7, -C(=O)R7, -C(=O)NR7R8, -OC(=O)NR7R8, -OC(=O)SR7, -SR7, -S(=O)R7, -S(=O)2R7, -S(=O)2NR7R8, y R7; R2 es H, -CH3, -CN o -C(=O)OR7; R3 es -C(=O)NR9-, -C(=O)O-, -C(=O)(CR10R11)n-, o -(CR10R11)n-; R4 es un alquilo C1-8 de cadena lineal o ramificada, un alquenilo C2-8 de cadena lineal o ramificada, un alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo (3-8 miembros), bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo (5-11 miembros), arilo C6-14, o heteroarilo (5-14 miembros); y donde R4 está opcionalmente sustituido con 1 a 3 sustituyentes R6 independientemente seleccionados de F, Cl, Br, I, nitro, ciano, -CF3, -NR7R8, -NR7C(=O)R8, NR7C(=O)OR8, -NR7C(=O)NR8R9, -NR7S(=O)2R8, -NR7S(=O)2NR8R9, -OR7, OC(=O)R7, -OC(=O)OR7, -C(=O)OR7, -C(=O)R7, -C(=O)NR7R8, -OC(=O)NR7R8, -OC(=O)SR7, -SR7, -S(=O)R7, -S(=O)2R7, -S(=O)2NR7R8, y R7; cada uno de R7, R8 y R9 se selecciona independientemente de H, alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo (3-8 miembros), bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo (5-11 miembros), arilo C6-14, y heteroarilo (5-14 miembros), donde R7, R8 y R9 están cada uno independientemente opcionalmente sustituidos con 1 a 6 sustituyentes independientemente seleccionados de F, Cl, Br, I, -NO2, -CN, -CF3, -NR10R11, -NR10C(=O)R11, -NR10C(=O)OR11, -NR10C(=O)NR11R12, -NR10S(=O)2R11, NR10S(=O)2NR11R12, -OR10, OC(=O)R10, -OC(=O)OR10, -OC(=O)NR10R11, -OC(=O)SR10, -SR10, -S(=O)R10, -S(=O)2R10, -S(=O)2NR10R11, -C(=O)R10, -C(=O)OR10, -C(=O)NR10R11 y R10; o, cuando R7 y R8 están como en NR7R8, ellos pueden, por el contrario, estar opcionalmente conectados para formar con el nitrógeno de NR7R8 al que está unido un resto heterocicloalquilo de 3 a 7 miembros en el anillo, comprendiendo dicho resto heterocicloalquilo opcionalmente 1 o 2 heteroátomos adicionales independientemente seleccionados de N, O y S; cada uno de R10, R11 y R12 se selecciona independientemente de H, alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo (3-8 miembros), bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo (5-11 miembros), arilo C6-14, y heteroarilo (5-14 miembros), donde R10, R11 y R12 están cada uno independientemente opcionalmente sustituidos con 1 a 6 sustituyentes independientemente seleccionados de F, Cl, Br, I, NO2, -CN, -CF3, -NR13R14, -NR13C(=O)R14, -NR13C(=O)OR14, -NR13C(=O)NR14R15, -NR13S(=O)2R14, -NR13S(=O)2NR14R15, -OR13, -OC(=O)R13, -OC(=O)OR13, -OC(=O)NR13R14, -OC(=O)SR13, -SR13, -S(=O)R13, -S(=O)2R13, -S(=O)2NR13R14, -C(=O)R13, -C(=O)OR13, -C(=O)NR13R14, y R13; cada uno de R13, R14 y R15 se selecciona independientemente de H, alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo (3-8 miembros), bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobiciciloalquilo (5-11 miembros), arilo C6-14, y heteroarilo (5-14 miembros), donde R13, R14 y R15 están cada uno independientemente opcionalmente sustituidos con 1 a 6 sustituyentes independientemente seleccionados de F, Cl, Br, I, NO2, -CN, -CF3, -NR16R17, -NR16C(=O)R17, -NR16C(=O)OR17, -NR16C(=O)NR17R18, -NR16S(=O)2R17, -NR16S(=O)2NR17R18, -OR16, -OC(=O)R16, -OC(=O)OR16, -OC(=O)NR16R17, -OC(=O)SR16, -SR16, -S(=O)R16, -(=O)2R16, -S(=O)2NR16R17, -C(=O)R16, - C(=O)OR16, -C(=O)NR16R17, y R16; cada uno de R16, R17 y R18 se selecciona independientemente de H, alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo (3-8 miembros), bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo (5-11 miembros), arilo C6-14, y heteroarilo (5-14 miembros), n es 0, 1, 2 o 3; donde R10 y R11 en -C(=O)(CR10R11)n- y -(CR10R11)n- se definen independientemente para cada valor de n como se ha detallado antes; y sus sales farmacéuticamente aceptables. Se indica que los compuestos de la fórmula (1) tienen actividad para inhibir las cdk5, cdk2, GSK-3. Proporciona composiciones farmacéuticas y métodos que comprenden compuestos de la fórmula (1) para tratar y prevenir enfermedades y condiciones que implican crecimiento celular anormal, tales como el cáncer, y enfermedades y condiciones neurodegenerativas y las afectadas por la neurotransmisión de la dopamina. También se describen composiciones farmacéuticas y métodos que comprenden compuestos de la fórmula (1) para tratar la fertilidad masculina y la motilidad espermática; diabetes mellitus; deterioro de la tolerancia a la glucosa; síndrome metabólico o síndrome X; síndrome de poliquistosis ovárica, adipogénesis y obesidad; miogénesis y fragilidad, por ejemplo el deterioro de las características físicas relacionado con la edad; sarcopenia aguda, por ejemplo atrofia muscular y/o caquexia asociada con la quemaduras, reposo en cama, inmovilización de miembros, o importante cirugía torácica, abdominal y/o ortopédica; sepsis; caída del cabello, cabello ralo y calvicie; e inmunodeficiencia.
ARP010104115A 2000-08-31 2001-08-29 Compuestos derivados de pirazol, composicion farmaceutica, compuestos intermediarios AR035345A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22941500P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
AR035345A1 true AR035345A1 (es) 2004-05-12

Family

ID=22861151

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104115A AR035345A1 (es) 2000-08-31 2001-08-29 Compuestos derivados de pirazol, composicion farmaceutica, compuestos intermediarios

Country Status (38)

Country Link
EP (1) EP1313710A1 (es)
JP (1) JP2004507526A (es)
KR (1) KR20030027093A (es)
CN (1) CN1518543A (es)
AP (1) AP2001002266A0 (es)
AR (1) AR035345A1 (es)
AU (1) AU2001280009A1 (es)
BG (1) BG107455A (es)
BR (1) BR0113574A (es)
CA (1) CA2420363A1 (es)
CR (1) CR6881A (es)
CZ (1) CZ2003468A3 (es)
DO (1) DOP2001000243A (es)
DZ (1) DZ3398A1 (es)
EA (1) EA200300205A1 (es)
EC (1) ECSP034480A (es)
EE (1) EE200300085A (es)
GT (1) GT200100179A (es)
HN (1) HN2001000192A (es)
HR (1) HRP20030140A2 (es)
HU (1) HUP0302669A3 (es)
IL (1) IL154016A0 (es)
IS (1) IS6687A (es)
MA (1) MA26946A1 (es)
MX (1) MXPA03001785A (es)
NO (1) NO20030958L (es)
NZ (1) NZ523656A (es)
OA (1) OA12368A (es)
PA (1) PA8528101A1 (es)
PE (1) PE20020470A1 (es)
PL (1) PL360742A1 (es)
SK (1) SK2002003A3 (es)
SV (1) SV2002000618A (es)
TN (1) TNSN01132A1 (es)
UY (1) UY26909A1 (es)
WO (1) WO2002018346A1 (es)
YU (1) YU14703A (es)
ZA (1) ZA200301064B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1317448B2 (en) 2000-09-15 2011-05-04 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP4160395B2 (ja) 2000-12-21 2008-10-01 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
WO2003026649A1 (en) * 2001-09-27 2003-04-03 Applied Research Systems Ars Holding N.V. Methods of increasing endogenous testosterone levels
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
CA2492673A1 (en) * 2002-07-17 2004-01-22 Pharmacia Italia S.P.A. Heterobicyclic pyrazole derivatives as kinase inhibitors
JP2006504725A (ja) 2002-10-09 2006-02-09 ファイザー・プロダクツ・インク 神経変性障害治療用ピラゾール化合物
US7582630B2 (en) * 2002-10-15 2009-09-01 Smithkline Beecham Corporation Pyradazine compounds as GSK-3 inhibitors
WO2004076414A2 (en) * 2003-02-27 2004-09-10 Smithkline Beecham Corporation Novel compounds
JP2007511203A (ja) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
US7759382B2 (en) * 2003-06-05 2010-07-20 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
WO2005012256A1 (en) 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
SI1663978T1 (sl) 2003-07-23 2008-02-29 Bayer Pharmaceuticals Corp Fluoro substituirana omega-karboksiaril difenil secnina za zdravljenje ali preprecevanje bolezni instanj
BRPI0412820A (pt) * 2003-07-25 2006-09-26 Pfizer compostos de aminopirazol e utilização como inibidores de chk1
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer
US7244757B2 (en) 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
WO2005103010A2 (en) * 2004-04-21 2005-11-03 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
WO2005110994A2 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US7521560B2 (en) 2004-06-29 2009-04-21 Rigel Pharmaceuticals, Inc. 2-substituted quinoline compounds and their uses
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
RU2007122485A (ru) 2004-11-17 2008-12-27 Мийкана Терапьютикс Ингибиторы киназы
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
PT1846394E (pt) 2005-02-04 2012-01-05 Astrazeneca Ab Derivados de pirazolilaminopiridina úteis como inibidores da quinase
US20090156582A1 (en) * 2005-02-09 2009-06-18 Tetsuya Tsukamoto Pyrazole Compound
BRPI0607455A2 (pt) 2005-02-16 2009-09-01 Astrazeneca Ab composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
EP1899323A2 (en) 2005-05-16 2008-03-19 AstraZeneca AB Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
KR20140025610A (ko) 2005-09-30 2014-03-04 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
PT1945631E (pt) 2005-10-28 2012-10-15 Astrazeneca Ab Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP5249771B2 (ja) 2005-11-03 2013-07-31 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリミジン
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2086642B1 (en) 2006-10-18 2014-06-25 Periness Ltd. Dnase for the treatment of male sub-fertility
CN101573352A (zh) 2006-10-21 2009-11-04 艾博特股份有限两合公司 杂环化合物和其作为糖原合酶激酶3抑制剂的用途
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
EP3078662A1 (en) 2007-09-21 2016-10-12 Array Biopharma, Inc. Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
JPWO2009130900A1 (ja) * 2008-04-24 2011-08-11 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
SG173178A1 (en) 2009-04-03 2011-09-29 Hoffmann La Roche Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
US20110081316A1 (en) * 2009-10-02 2011-04-07 Vertex Pharmaceuticals Incorporated Pyrazole inhibitors of phosphatidylinositol 3-kinase
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
RS58455B1 (sr) 2011-02-07 2019-04-30 Plexxikon Inc Jedinjenja i postupci za modulaciju kinaze, i indikacije za njih
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP3033339B1 (en) 2013-08-16 2018-02-28 Merck Patent GmbH 3-substituted cyclopentylamine derivatives
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
US11084825B2 (en) 2018-12-31 2021-08-10 Biomea Fusion, Llc Substituted pyridines as irreversible inhibitors of menin-MLL interaction
EP3906029A4 (en) 2018-12-31 2022-09-21 Biomea Fusion, LLC INHIBITORS OF MENIN-MLL INTERACTION
JP7094456B2 (ja) * 2019-01-31 2022-07-01 ファイザー・インク Ｃｄｋ２阻害剤
TW202229268A (zh) * 2020-12-22 2022-08-01 大陸商上海拓界生物醫藥科技有限公司 Ｃｄｋ２抑制劑及其製備方法
MX2023013173A (es) 2021-05-07 2023-11-30 Kymera Therapeutics Inc Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos.
US11932648B2 (en) 2021-06-28 2024-03-19 Blueprint Medicines Corporation CDK2 inhibitors
TW202317564A (zh) * 2021-07-01 2023-05-01 大陸商上海拓界生物醫藥科技有限公司 Cdk2抑制劑及其製備方法和用途
MX2024002189A (es) 2021-08-20 2024-06-11 Biomea Fusion Inc Forma cristalina de n-[4-[4-(4-morfolinil)-7h-pirrolo[2,3-d]pirimi din-6-il]fenil]-4-[[3(r)-[(1-oxo)-2-propen-1-il)amino]-1-piperidi nil]metil]-2-piridinacarboxamida, un inhibidor irreversible de menina-mll para el tratamiento del cancer.
TW202325280A (zh) * 2021-11-09 2023-07-01 大陸商上海拓界生物醫藥科技有限公司 一種胺基吡唑衍生物及其製備方法和用途
WO2023092088A1 (en) * 2021-11-19 2023-05-25 Blueprint Medicines Corporation Cdk2 inhibitors and methods of making and using same
WO2023239629A1 (en) * 2022-06-06 2023-12-14 Plexium, Inc. Compounds and pharmaceutical compositions that degrade cdk2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100571588B1 (ko) * 1997-12-22 2006-04-17 바이엘 코포레이션 치환 헤테로시클릭 우레아를 이용한 ｒａｆ 키나제의 억제
KR100579792B1 (ko) * 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
EP1199306B1 (en) * 1999-07-26 2005-12-07 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
EA005373B1 (ru) * 1999-08-12 2005-02-24 Фармация Италия С.П.А. Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств
CN1402720A (zh) * 1999-11-30 2003-03-12 辉瑞产品公司 用作免疫抑制剂的2,4－二氨基嘧啶化合物
MXPA02010222A (es) * 2000-04-18 2003-05-23 Agouron Pharma Pirazoles para inhibir proteina cinasa.

Also Published As

Publication number Publication date
BR0113574A (pt) 2003-07-22
AU2001280009A1 (en) 2002-03-13
EP1313710A1 (en) 2003-05-28
KR20030027093A (ko) 2003-04-03
CZ2003468A3 (cs) 2004-05-12
HUP0302669A3 (en) 2004-03-29
BG107455A (en) 2003-09-30
IL154016A0 (en) 2003-07-31
CR6881A (es) 2004-03-11
JP2004507526A (ja) 2004-03-11
UY26909A1 (es) 2002-03-22
EE200300085A (et) 2004-12-15
CN1518543A (zh) 2004-08-04
SV2002000618A (es) 2002-10-24
HN2001000192A (es) 2001-08-28
IS6687A (is) 2003-01-16
ZA200301064B (en) 2004-04-19
DOP2001000243A (es) 2002-10-15
SK2002003A3 (en) 2004-04-06
HRP20030140A2 (en) 2003-04-30
PL360742A1 (en) 2004-09-20
AP2001002266A0 (en) 2001-09-30
YU14703A (sh) 2006-05-25
MXPA03001785A (es) 2003-06-04
DZ3398A1 (fr) 2002-03-07
GT200100179A (es) 2002-04-22
CA2420363A1 (en) 2002-03-07
EA200300205A1 (ru) 2003-06-26
WO2002018346A1 (en) 2002-03-07
NZ523656A (en) 2004-11-26
HUP0302669A2 (hu) 2003-12-29
PE20020470A1 (es) 2002-06-18
ECSP034480A (es) 2003-03-31
OA12368A (en) 2004-04-13
PA8528101A1 (es) 2002-07-30
TNSN01132A1 (fr) 2005-11-10
NO20030958D0 (no) 2003-02-28
NO20030958L (no) 2003-02-28
MA26946A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
AR035345A1 (es) Compuestos derivados de pirazol, composicion farmaceutica, compuestos intermediarios
AR032629A1 (es) Compuestos derivados de imidazol y composicion farmaceutica que los contiene
ECSP099437A (es) Composición herbicida
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
AR057979A1 (es) PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
AR067397A1 (es) Derivados de triazol con actividad anticancerigena
AR041250A1 (es) Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa
PE20070243A1 (es) Compuestos heterociclicos como inhibidores de la transcriptasa reversa de vih
HUP0400266A2 (hu) Imidazo[1,2-a]piridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk herpeszvírus-fertőzések megelőzésére vagy kezelésére
AR054625A1 (es) Compuestos de oxazolidinona,procedimiento para prepararlos,composiciones farmaceuticas que los contienen,y uso como agentes antimicrobianos.
AR037754A1 (es) Herbicidas
AR035436A1 (es) Una benzofenona o derivado farmaceuticamente aceptable, sales, formas salinas, composiciones farmaceuticas, usos para la fabricacion de un medicamento, y proceso para la preparacion de una benzofenona
ATE315555T1 (de) Thiazolderivate und ihre verwendung als cdk- inhibitoren
ATE507217T1 (de) Pyrimidinverbindung und diese enthaltende medizinische zusammensetzung
AR063800A1 (es) Derivados de acido nicotinico, composiciones farmaceuticas que las contienen y metodos de uso de los mismos
CO6260070A2 (es) Entidades quimicas de imidazopiridina paea el tratamiento de infecciones con hepatitis c
PE20090151A1 (es) Derivados de pirimidinona y metodos para su uso
AR047702A1 (es) Imidazol-5-il-anilinopirimidinas como agentes inhibidores de la proliferacion celular
AR019788A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso y procedimientos para prepararlos
PE20140471A1 (es) Moduladores de la via del complemento y usos de los mismos
CA2437524A1 (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
AR064345A1 (es) Derivados de 8-oxoadenina
AR040413A1 (es) Heterociclilalquinos activos como herbicidas
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
EA200601287A1 (ru) Производные (3-оксо-3,4-дигидрохиноксалин-2-иламино) бензамида и родственные соединения в качестве ингибиторов гликогенфосфорилазы для лечения диабета и ожирения

Legal Events

Date Code Title Description
FB Suspension of granting procedure